炎症因子及血生化指标在支架内再狭窄中作用的研究进展#br#

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract This paper describes the inflammatory factors and blood biochemical indexes that have an impact on in-stent restenosis(ISR). First, the mechanism of ISR is briefly reviewed. On the basis of the above, we summarize the latest progress in the study of inflammatory factors affecting ISR, and review the research on blood biochemical indexes affecting ISR. Up to now, no review has been made on the influence of blood biochemical indexes on ISR. Finally, we discuss the pathological significance of the inflammatory factors in ISR, and the clinical value of practical and predictive efficacy of blood biochemical indexes for ISR.

Key words： Vascular disease Stents Constriction, pathologic

Received: 26 August 2016

PACS:	Ｒ543
	R815

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Hai-rui
	LIU Zhao-yu

Cite this article:

WANG Hai-rui,LIU Zhao-yu. Research progress of inflammatory factors and blood biochemical indexes in in-stent restenosis[J]. JOURNAL OF CHINA MEDICAL IMAGING, 2017, 28(4): 294-297.

URL:

http://www.jccmi.com.cn/EN/ OR http://www.jccmi.com.cn/EN/Y2017/V28/I4/294

[1]Kang SJ, Mintz GS, Park DW, et al. Mechanisms of In-Stent Restenosis After Drug-Eluting Stent Implantation Intravascular Ultrasound Analysis[J]. Circ Cardiovasc Interv, 2011, 4(1): 9-14.
[2]Ross R. Atherosclerosis an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126.
[3]江涛. P-选择素和内皮素1在下肢动脉硬化闭塞症患者介入治疗术后的表达[D]. 安徽：安徽医科大学，2012.
[4]冯晓东，蔡英年. 内皮素-1对血管平滑肌细胞增殖作用的研究进展[J]. 中国应用生理学杂志，1994，10（2）：189-191.
[5]任为，张彦，时德. 血浆内皮素与慢性下肢动脉缺血的相关性研究[J]. 重庆医科大学学报，2002，27（4）：439-440.
[6]史作磊，王坤，于剑，等. 血浆内皮素-1及NO对膝下动脉硬化闭塞症球囊扩张成形术后血管再狭窄的预测价值[J]. 中国现代普通外科进展，2015，2（18）：127-129.
[7]Fiessinger JN, Schafer M. Trial of iloprost versus aspirin treatmentfor critical limb ischaemia of thromboangiitisobliterans: the TAO Study[J]. Lancet, 1990, 335(8689): 555-557.
[8]Dormandy J. Use of the prostacyclin analogue iloprost in the treatment of patients with critical limb ischaemia[J]. Therapie, 1991, 46(4): 319-322.
[9]Lessiani G, Vazzana N, Cuccurullo C, et al. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost[J]. Thromb Haemost, 2011, 105(2): 321-328.
[10]Miyashita Y, Saito S, Miyamoto A, et al. Cilostazol increases skin perfusion pressure in severely ischemic limbs[J]. Angiology, 2011, 62(1): 15-17.
[11]Shalhoub J, Davies AH, Franklin IJ. Cilostazol may improve outcome in critical limb ischemia[J]. Int Angiol, 2009, 28(5): 363-366.
[12]Sigvant B, Wiberg-Hedman K, Bergqvist D, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences[J]. J Vasc Surg, 2007, 45(6): 1185-1191.
[13]Folsom AR, Pankow JS, Tracy RP, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease[J]. Am J Cardiol, 2001, 88(2): 112-117.
[14]何文军，黄家平，梁伟东，等. 氧化低密度脂蛋白和C-反应蛋白与冠状动脉支架置入术后再狭窄的关系研究[J]. 检验医学，2015，30（5）：484-488.
[15]Hojo Y, Ikeda U, Katsuki T, et al. Interleukin 6 expression incoronary circulation after coronary angioplasty as a risk factor for restenosis[J]. Heart, 2000, 84(1): 83-88.
[16]Dibra A, Mehilli J, Braun S, et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting[J]. Am J Med, 2003, 114(9): 715-722.
[17]Tzoulaki I, Murray GD, Lee AJ, et al. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study[J]. Eur Heart J, 2007, 28(3): 354-362.
[18]Zurakowski A, Wojakowski W, Dzielski T, et al. Plasma levels of C-reactive protein and interleukin-10 predict late coronary in-stent restenosis 6 months after elective stenting[J]. Kardiol Pol, 2009, 67(6): 623-630.
[19]Funayama H, Ishikawa SE, Kubo N, et al. Close association of regional interleukin-6 levels in the infarct-related culprit coronary artery with restenosis in acute myocardial infarction[J]. Circulation, 2006, 70(4): 426-429．
[20]吕磊，张柏根. 白细胞介素12促血管平滑肌细胞增殖的实验研究[J]. 中国现代医学杂志，2008，15（18）：2138-2141.
[21]Anguera I, Miranda-Guardiola F, Bosch X, et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina[J]. Am Heart J, 2002, 144(5): 811-817.
[22]Smith DA, Irving SD, Sheldon J, et al. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina[J]. Circulation, 2001, 104(7): 746-749.
[23]Feldman LJ, Aguirre L, Ziol M, et al. Interleukin 10 inhibits intimal hyperplasia after angioplasty or stent implantation in Hypercholesterolemic rabbits[J]. Circulation, 2000, 101(8): 908-916.
[24]Kaikita K, Ogawa H, Yasue H, et al. Soluble P-selectin is released into the coronary circulation after coronary spasm[J]. Circulation, 1995, 92(7): 1726-1730．
[25]苏子德，代怀静，王涛，等. 血浆P-选择素和内皮素-1预测冠状动脉内支架术后早期再狭窄的价值[J]. 中国介入心脏病学杂志，2006，14（4）：222-225.
[26]Shinkai S, Chaves PH, Fujiwara Y, et al. Beta 2-microglobulin for risk stratification of total mortality in the elderly population：comparison with cystatin C and C-reactive protein[J]． Arch intern Med, 2008, 168(2): 200-206．
[27]Touefsen DM. Vascular dermatan sulfate and heparin cofactor Ⅱ[J]. Prog Mol Biol Transl Sci, 2010, 93: 351-372．
[28]秦永林，滕皋军，郭金和，等. 下肢动脉球囊扩张成形术后血清β2微球蛋白变化及其对再狭窄或闭塞的预测作用[J]. 中华医学杂志，2012，21（92）：1453-1457.
[29]卢衡，郭平凡. 血清肝素辅助因子Ⅱ活性与下肢动脉硬化闭塞症介入术后再狭窄相关[J]. 中南大学学报：医学版，2015，40（2）：177-181.
[30]Benaron DA, Bowen FW. Varition of intial serum bilirubin rise in newborn infants with type of illness[J]. Lancet, 1991, 338(8759): 78．
[31]丁乐顺，刘占成. 血清胆红素检测与动脉粥样硬化的关系[J]. 江西医学检验，2005，23（3）：272-273.
[32]刘昆，辛世杰，张健，等. 贫血与下肢动脉硬化闭塞症相关性研究[J]. 中国血管外科杂志：电子版，2012，4（3）：161-162.
[33]Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction[J]. J Am Coll Cardiol, 2001, 38(4): 955-962.
[34]Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure[J]. Circulation, 2003, 107(2): 223-225.
[35]Wang XY, Qiu MH, Li J, et al. Impacts of anemia on 3-year ischemic events in patients undergoing percutaneous coronary intervention: a propensity matched study[J]. J Thorac Dis, 2015, 7(11): 1951-1959.
[36]王海君，刘冰，王海洋，等．胆红素、尿酸水平与下肢动脉硬化闭塞症相关性研究[J]．中国血管外科杂志：电子版，2010，2（1）：45－49．
[37]Desormais I, Aboyans V, Bura A, et al. Anemia, an independent predictive factor for amputation and mortality in patients hospitalized for peripheral artery disease[J]. Eur J Vasc Endovasc Surg, 2014, 48(2): 202-207.
[38]Toso A, Leoncini M, Maioli M, et al. Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction[J]. J Cardiovasc Med, 2011, 12(5): 318-321．